Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. - Wikidata - wikimedia - TriplyDB

Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina.

Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina.

http://www.wikidata.org/entity/Q46404474

about

Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials Updates on the Clinical Trials in Diabetic Macular Edema Steroids in Central Retinal Vein Occlusion: Is There a Role in Current Treatment Practice?Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant The role of aflibercept in the management of diabetic macular edema Dexamethasone intravitreal implant in the treatment of diabetic macular edema The multifactorial nature of retinal vascular disease Diabetic macular edema: new concepts in patho-physiology and treatment.Upcoming therapeutic advances in diabetic macular edema: an intravitreal dexamethasone drug delivery system.Adult coats' disease successfully managed with the dexamethasone intravitreal implant (ozurdex®) combined with retinal photocoagulation.Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy Pathophysiology and treatment of diabetic retinopathy.Correlation between decreased choroidal blood flow velocity and the pathogenesis of acute zonal occult outer retinopathy.Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).Antagonism of CD11b with neutrophil inhibitory factor (NIF) inhibits vascular lesions in diabetic retinopathy.Efficacy and safety of different doses of a slow-release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.Morphology and Function over a One-Year Follow Up Period after Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema.Decrease in retinal neuronal cells in streptozotocin-induced diabetic mice.Progression of Diabetic Capillary Occlusion: A Model.Evidence-Based Treatment of Diabetic Macular Edema.Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up.Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections.Vascular adhesion protein 1 in the eye.Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes.Intravitreal triamcinolone acetonide: Pattern of secondary intraocular pressure rise and possible risk factors.Cytoplasmic translocation of high-mobility group box-1 protein is induced by diabetes and high glucose in retinal pericytes Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy.Ruboxistaurin: PKC-beta inhibition for complications of diabetes.Anti-inflammatory therapy for diabetic retinopathy.Fluocinolone acetonide for the treatment of diabetic macular edema.Coat's-like exudation in rhodopsin retinitis pigmentosa: successful treatment with an intravitreal dexamethasone implant An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy.Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas.Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles.Panretinal Photocoagulation Using Short-Pulse Laser Induces Less Inflammation and Macular Thickening in Patients with Diabetic Retinopathy Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema.Combined Intravitreal Dexamethasone Implant And Micropulse Yellow Laser For Treatment Of Anti-VEGF Resistant Diabetic Macular Edema.

P2860

Q24658545-0CAB20F2-7455-408A-AE77-D8B38E00A41D Q26767100-2D7E9174-4A4B-4F28-AA96-CFAAB88599B1 Q26774524-36EC9AA6-0A56-495F-9F70-F9A2E8C10DAE Q26775853-63403732-78EB-4AB8-9B93-44998C594870 Q26798348-AA6B801E-D10A-4FE5-AAE9-37BE695A682F Q26799423-1EDF29DF-9F66-4B12-8232-D105EFE8ECBA Q33660130-03C42B1B-8D45-4FDA-9628-0ED35A9A463C Q33713517-D749FC86-C158-45E2-BB43-5826B8DC9ED9 Q33790255-BCB94D78-11A0-42E3-A0CD-B719B82BC985 Q34252617-AB1F0893-3D7E-4758-99E3-F1FD2A8EA77E Q34426246-5DE249BB-6CE1-4165-B0B9-72EABB0080C5 Q34528134-CC8283F8-C456-4CAF-81E9-74B1CB5704C0 Q34777421-75F2FDA2-40DD-49CC-85D4-17ECF79ECB0F Q35030923-A907AC46-C2CE-4BAA-926F-0D073BC4542F Q35036412-F815C6DB-79F6-449C-A11D-FFD2ED3C9AFF Q35594036-419A0B3D-D159-41E8-89D1-DAB662F34CF5 Q35828114-00FABC59-6C15-4E7E-AEE5-B2512E953F06 Q35882571-99DC2858-9B96-423A-B81E-2A31C25DB64E Q36015795-95D92A53-4B02-42E9-9B54-B82952EE4023 Q36051940-429622B3-D179-4A3E-8890-1086D92AC44D Q36242390-91A70F17-A557-4E34-BC71-D97AE782E4E3 Q36341458-EAAC8E20-70F5-4D49-8B82-DD5AB780DE49 Q36856905-5C043E46-E740-47A4-B232-413C04281DB9 Q36906893-4B5880F7-66A2-440C-9633-E6D06B848375 Q36942812-E4D51BBC-2E3A-4C9D-90D6-54E144F66331 Q37084522-EE80097B-30C4-42D3-BEB7-15CF4BB8BB26 Q37095335-8E34592E-D43C-47CB-99BB-3F028EEABE2F Q37221486-B4CDA87A-099B-485C-8A02-C1BBF08706BF Q37297418-2469CAA0-A968-458B-91A7-C89BB0BF917A Q37416874-67D103AE-42D5-4B31-8E49-06DF2E8F74F6 Q37636163-256B4B9A-89C8-4372-AEF5-7FE32F37351F Q37873482-0B26F061-5ED7-4613-8265-4E72DF66EC4F Q38648612-1C35CBCD-8F2C-44A9-A984-09AF1A8A6174 Q38709587-D82C683F-3A4F-4CBB-8814-9FBA4FEFBEFF Q39225517-F5BE0CF4-7C78-48FF-B1CE-8CA3BE8AB65C Q39545613-A56DAA83-BD34-4DAB-8461-22D81E753B25 Q40010634-74623E3F-E9CA-48E9-B5CF-33FBA556E9B7 Q41067724-B41B9375-6D38-41A5-9383-88791772CCD0 Q41236033-77C6F6E9-19ED-45DE-B82F-1A5BBF64C949 Q41250047-606977FA-0C98-43A5-8CAE-B72299F78854

P2860

Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina.

http://www.wikidata.org/entity/Q46404474

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Intravitreal injection of cort ...... experimental diabetic retina.

@en

Intravitreal injection of cort ...... experimental diabetic retina.

@nl

type

label

Intravitreal injection of cort ...... experimental diabetic retina.

@en

Intravitreal injection of cort ...... experimental diabetic retina.

@nl

prefLabel

Intravitreal injection of cort ...... experimental diabetic retina.

@en

Intravitreal injection of cort ...... experimental diabetic retina.

@nl

P1433

Q46404474-083FCC45-BDF5-4B11-BF74-FBE6472E65B6

P1476

Q46404474-B4256D43-8B6A-4F5A-A450-4C78E36EE15A

P2093

Q46404474-158271E5-22F1-413F-9245-C43DDF075DFE

Q46404474-4BA0D09B-663F-4BE8-B84B-12ADB53F5F60

Q46404474-5A5E4506-9E22-44DB-BFFD-821AE465313A

Q46404474-5D6E0AF8-A4FA-4927-B3AA-E84054372978

Q46404474-D79ED490-AE01-4633-83D5-B25D979B6A4C

Q46404474-D95F0659-95AE-46DD-9F33-15ADD03010F4

Q46404474-E5E51866-74DC-487B-B81B-DC8FF339123A

P304

Q46404474-D14FF66A-014D-48CD-8DB8-F055BD32B158

P31

Q46404474-057B3019-3EE5-4A9F-AFD4-BAE9A2CD1E94

P356

Q46404474-B5D5E19A-F7B2-40C4-AA2D-46DAB481B91E

P407

Q46404474-2687145D-9870-4AD8-A595-615C13A49EA4

P433

Q46404474-9244593D-6CA9-449E-90F5-A0256E1DFFFA

P478

Q46404474-30135E08-2A18-4211-9270-6B85CB3359C8

P50

Q46404474-D6F16C7C-ECC2-465B-80BE-1B723AC5F126

P577

Q46404474-38273F6E-B9CF-434A-948E-EB2915E0D89A

P698

Q46404474-48CC0088-F7E5-4EA2-B43B-3D0774B4BA82

P356

P1433

Investigative Ophthalmology & Visual Science

P1476

Intravitreal injection of cort ...... experimental diabetic retina.

@en

P2093

Fumitaka Hirose

http://www.w3.org/2001/XMLSchema#string

Hideto Katsuta

http://www.w3.org/2001/XMLSchema#string

Hiroshi Tamura

http://www.w3.org/2001/XMLSchema#string

Junichi Kiryu

http://www.w3.org/2001/XMLSchema#string

Kazuaki Miyamoto

http://www.w3.org/2001/XMLSchema#string

Kunihiro Musashi

http://www.w3.org/2001/XMLSchema#string

Shinsuke Miyahara

http://www.w3.org/2001/XMLSchema#string

P304

1440-1444

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1167/IOVS.04-0905

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Nagahisa Yoshimura

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15790913

http://www.w3.org/2001/XMLSchema#string